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Heidelberg, GermanyOBJECTIVES We sought to evaluate noninvasive parameters by electrocardiography, echocardiog-
raphy, technetium-99m–3,3-diphosphono-1,2-propanodicarboxylic acid (99mTc-DPD) scintigraphy, and
cardiac magnetic resonance for the prediction of all-cause mortality in patients with cardiac transthyretin
amyloidosis (ATTR).
BACKGROUND ATTR may present with highly variable symptoms, including polyneuropathy and
cardiomyopathy, the latter being associated with a poor outcome. However, data on noninvasive risk
stratiﬁcation of ATTR are limited.
METHODS A total of 70 patients with ATTR were evaluated by echocardiography, cardiac biomarkers,
and 99mTc-DPD scintigraphy. Cardiac magnetic resonance was performed in 30 patients. Echocardio-
graphic ﬁndings and plasma levels of biomarkers were correlated with results of quantitative analysis of
scintigraphy using a region-of-interest technique (whole-body as well as heart tracer retention). Receiver-
operating characteristic (ROC) analysis was performed to calculate a cutoff value of 99mTc-DPD scinti-
graphy for heart retention for the diagnosis of cardiac amyloid involvement with the highest sensitivity
and speciﬁcity. Univariate and multivariate analyses were performed in patients with cardiac involvement
(n ¼ 60) to determine noninvasive predictors of all-cause mortality.
RESULTS Scintigraphy ﬁndings correlated with morphological (interventricular septum thickness, left
ventricular hypertrophy index) as well as functional (mitral annular systolic velocity, mitral/tricuspid
annular plane systolic excursion) ﬁndings, cardiac biomarkers, renal function, and late gadolinium
enhancement. The ROC-derived cutoff for the detection of cardiac amyloidosis by scintigraphic heart
tracer retention was 4.8%. Univariate Cox regression revealed N-terminal pro–B-type natriuretic peptide,
troponin T, mitral annular plane systolic excursion, and left ventricular hypertrophy index as predictors of
all-cause mortality. However, on multivariate analysis, troponin T remained the only independent predic-
tor of survival. The ROC-derived cutoff value of troponin T predicting all-cause mortality with the highest
sensitivity (80.0%) and speciﬁcity (68.7%) was 0.0375 ng/l.
CONCLUSIONS Quantitative analysis of tracer retention is capable of characterizing the severity of
cardiac involvement in ATTR. Bymultivariate analysis, troponin T remained the only independent predictor
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503uman transthyretin (TTR) is the amyloid
precursor protein in transthyretin amyloid-
osis (ATTR). TTR usually forms a tetramer
that is capable of binding thyroxine, whereas
the monomeric form, which is rich in beta sheets,
readily forms amyloid ﬁbrils. More than 100 TTR
point mutants are known to be amyloidogenic includ-
ing the most common mutation, Val30Met (substi-
tution of methionine for valine at position 30) (1).See page 511
A B B R E V I A T I O N S
A N D A C R O N YM S
ATTR = transthyretin
amyloidosis
CMR = cardiac magnetic
resonance
eGFR = estimated glomerular
ﬁltration rate
HR = heart, sternum, and
thoracic spine tracer retention
LV = left ventricular
NT-proBNP = N-terminal pro–B-
type natriuretic peptide
ROC = receiver-operating
characteristic
SSA = senile systemic
amyloidosis
99mTc-DPD = technetium-99m–
3,3-diphosphono-1,2-
propanodicarboxylic acid
TTR = transthyretin
TTR-FAC = transthyretin familial
amyloidotic cardiomyopathy
WBR = whole-body retentionDepending on the speciﬁc genotype, sex, endemic
area, and composition of amyloid ﬁbrils (2,3), they
predispose to the development of a preferentially
sensorimotor polyneuropathy (TTR familial amyloi-
dotic polyneuropathy) and/or (restrictive) cardiomyop-
athy (transthyretin familial amyloidotic cardiomyopathy
[TTR-FAC]) (4–9). Moreover, cardiac deposition of
wild-type TTR amyloid is a common aging phe-
nomenon named senile systemic amyloidosis (SSA)
(10) that is found in 25% of post-mortem cardiac bi-
opsy specimens from patients older than 85 years of
age. It is predominantly characterized by symptoms of
heart failure.
Cardiac involvement represents the major
complication of ATTR, either of the hereditary or
wild type (2,9,11), even though the median survival
of patients with ATTR appears to be much better
than that of individuals with light-chain amyloidosis
(12). At present, clinical variables that are poten-
tially useful for assessment of disease severity and
prognosis in ATTR patients are not elucidated in
detail (13–18).
Technetium-99m–3,3-diphosphono-1,2-prop-
anodicarboxylic acid (99mTc-DPD) scintigraphy is
a well standardized and widely available technique
for skeletal imaging. Recently, it was demonstrated
as a tool for noninvasive imaging of cardiac amyloid
deposits in patients with ATTR, yielding a high
diagnostic sensitivity (19). Minor tracer retention
can be found in patients with advanced cardiac
light-chain amyloidosis (20). The clinical value of
99mTc-DPD for prediction of outcome in ATTR
has not been evaluated in detail (21). Thus, the
impact of clinical, electrocardiographic, echocar-
diographic, scintigraphic, and cardiac magnetic
resonance (CMR) variables for risk stratiﬁcation
were investigated in patients with ATTR.
METHODS
Between September 2005 and July 2012, 70
consecutive patients (53 male, 17 female; mean age62.1  2.1 years) with ATTR (TTR-FAC: n ¼ 36;
SSA: n ¼ 34) were evaluated at the outpatient
department of Heidelberg Amyloidosis Center,
Heidelberg, Germany. All patients had biopsy-
proven ATTR (heart: n ¼ 53; rectum: n ¼ 10;
abdominal fat: n ¼ 3; nerve: n ¼ 3; and urinary
bladder: n ¼ 1). Amyloid was conﬁrmed by green
birefringence of Congo red–stained sections viewed
in polarized light and characterized by immuno-
histological staining. All patients underwent screening
for hereditary ATTR by isoelectric focusing of serum
and sequencing of genomic deoxyribonucleic acid
after a written informed consent was obtained (22).
Furthermore, a serum/urine immunoﬁxation elec-
trophoresis and a serum-free light-chain test were
performed. If both a clonal light-chain and
a mutant TTR were excluded, a diagnosis
of SSA was made. All patients were eval-
uated by echocardiography with Doppler
studies, 99mTc-DPD scintigraphy, and
standard blood tests including N-terminal
pro–B-type natriuretic peptide (NT-
proBNP) (Elecsys proBNP, Roche Di-
agnostics, Mannheim, Germany) as well as
troponin T (fourth-generation assay, Elec-
sys Troponin T, Roche Diagnostics).
CMR was performed in 30 of 70 patients.
Cardiac involvement was deﬁned as a
cardiac biopsy specimen containing amy-
loid or by myocardial wall thickening on an
echocardiogram in the absence of any
history of arterial hypertension or valvular
heart disease in patients with extracardiac
amyloidosis proven by positive Congo red
staining of any tissue specimen. Follow-up
for analysis of all-cause mortality was done
either by a personal visit to or other forms
of communication with the Heidelberg
Amyloidosis Center (n ¼ 48). If no follow-
up information was available for at least 3 months
(n ¼ 19), a telephone call was made at the end of
the observation period (July 31, 2013). Three of
these patients were lost during follow-up.
Echocardiography. All transthoracic echocardio-
graphic imaging was performed by experienced
investigators using a commercially available ultra-
sound machine (Vivid 7, GE Healthcare, Milwau-
kee, Wisconsin). Morphological and functional
evaluation of cardiac chambers was performed
according to the recommendations of the American
Society of Echocardiography (23–26). Left ven-
tricular (LV) ejection fraction was calculated by the
modiﬁed Simpson method (25) and was considered
markedly impaired if it was <40%. All recordings
Figure 1. Representative Image of a Whole-Body Scan by
99mTc-DPD Scintigraphy
Detection of technetium-99m–3,3-diphosphono-1,2-propanodicarboxylic
acid (99mTc-DPD) heart retention in a patient with a Val20Ile variant of
the transthyretin gene.
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504were averaged over 3 consecutive cardiac cycles.
In patients who were in atrial ﬁbrillation, 5 conse-
cutive beats were averaged. LV and right ventricular
longitudinal function was assessed from the apical
4-chamber view by mitral annular plane systolic
excursion (MAPSE) and tricuspid annular plane
systolic excursion (TAPSE) by measuring the
maximal excursion of the lateral site of the annulus
after ventricular systole by M-mode imaging.
Pulsed-wave tissue Doppler imaging of the mitral
annulus was performed using a standard spectral
Doppler sample volume gate length of 0.17 cm. The
sample volume was placed on the medial mitral
annulus in the apical 4-chamber view to measure
mitral annular systolic velocity. LV hypertrophy
index was calculated as the mean of the septal and
posterior wall divided by one-half of LV end-
diastolic diameter (normal range 0.33 to 0.41) (27).
99mTc-DPD scintigraphy. The procedure essentially
followed the protocol described for the ﬁrst time in
2002 (19). Preparation of 99mTc-DPD and quality
control were carried out according to the procedures
described by the manufacturer (CIS Bio Interna-
tional, Gif-sur-Yvette, France). For whole-bodystudies, a dual-head, whole-body gamma camera
system (Siemens ECAM, Siemens Medical Sys-
tems, Hoffmann Estates, Illinois) was used.
The patients received 555 MBq 99mTc-DPD
intravenously after urination. Whole-body scans
were conducted both 5 min (soft-tissue phase) and
3 h (bone phase) after injection of 99mTc-DPD
(Fig. 1). Tracer retention was assessed semi-
quantitatively using a region-of-interest technique of
planar images. All regions of interest were drawn by
an independent investigator who was unaware of the
patients’ clinical data. The anterior image was copied
to the posterior image and mirrored horizontally.
The geometric mean of counts measured in the
anterior and posterior projections was used in all
further calculations. All regions of interest were
corrected for background activity. Rectangular re-
gions of interest were placed over the heart in the
ﬁrst scan and copied to the images obtained 3 h after
injection. Irregular regions of interest were drawn
over the bladder and urinary tract in the early and
late images. Total registered counts in the whole-
body region of interest at 5 min after injection
were assumed to represent total injected activity.
Counts in the whole-body region of interest at 3 h
after injection, after subtraction of counts in bladder
and urinary tract and normalization for scan speed,
were decay corrected and compared with this value,
resulting in the percentage of whole-body tracer
retention (WBR). Counts in the heart region of
interest at 3 h after injection were decay corrected
and compared with whole-body counts at 5 min,
indicating the relative percentage of tracer retention
in the heart, sternum, and thoracic spine (HR).
Cardiac magnetic resonance. CMR was performed
on a 1.5-T whole-body MRI scanner (Achieva,
Philips Medical Systems, Best, the Netherlands), as
described previously (28). In brief, resting LV func-
tion was determined by standard steady-state free-
precession cine images in short axes, 2-, 3-, and
4-chamber views. Late gadolinium contrast agent
(0.2 mmol/kg body weight) (Magnevist, Bayer-
Schering-Pharma, Berlin, Germany) was adminis-
tered if the estimated glomerular ﬁltration rate was
>30 ml/(min  1.73 m2) (n ¼ 67). All data were
analyzed in a blinded fashion by consensus reading
(F.S., H.S.). Short-axis LV parameters were end-
diastolic and -systolic volumes, ejection fraction,
stroke volume, and LV myocardial mass. Longitudi-
nal function was assessed by MAPSE and TAPSE.
Regional LV wall thickness was analyzed in a modi-
ﬁed American Heart Association-16 segment model.
Late gadolinium enhancement was analyzed semi-
quantitatively (0 ¼ absent, 1 ¼ mild, 2 ¼ moderate,
Table 1. Clinical Demographics of the Patients With ATTR at Presentation
All Patients
(N [ 70)
TTR-FAC
(n [ 36)
SSA
(n [ 34) p Value
Cardiac
Involvement
(n [ 60)
Male 53 (75.5) 20 (59) 33 (97) <0.0001 47 (78)
Age, yrs 67.4 [16.9] 55.1 [17.1] 72.0 [4.8] <0.0001 68.2 [18.8]
MBMI, kg/m2  g/l 1,104 [313] 1,060 [417] 1,183 [262] 0.0503 1,104 [299]
NYHA functional class
I 16 (22.9) 14 (39.0) 2 (6.0) 0.0010 8 (13.3)
II 27 (38.6) 12 (33.0) 15 (44.0) 0.3537 25 (41.6)
III 26 (37.1) 10 (28.0) 16 (47.0) 0.0955 26 (43.3)
IV 1 (1.4) 0 (0.0) 1 (3.0) NA 1 (1.7)
eGFR,
ml/(min  1.73 m2)
71.1 [42.3] 93.8 [45.3] 62.3 [26.1] <0.0001 75.1 [40.9]
Troponin T, mg/l 0.03 [0.045] 0.02 [0.03] 0.06 [0.09] 0.0007 0.04 [0.04]
NT-proBNP, ng/l 1,950 [3,982] 907 [2,081] 4,010.5 [3,725] <0.0001 2,446 [3,452]
Sinus rhythm 53 (75.7) 32 (89.0) 21 (62.0) 0.0082 43 (71.7)
P-Q interval, ms 185 [50.0] 172 [42.0] 220 [52.5] <0.0001 197 [52.0]
QRS duration, ms 106 [42.0] 96.5 [33.5] 116 [50.5] 0.0027 106 [26.5]
Low-voltage pattern 7 (10.0) 2 (6.0) 5 (15.0) 0.1462 6 (10.0)
IVS thickness, mm 17 [5.3] 16.0 [7.5] 20 [5.25] 0.0009 19 [5.0]
PW thickness, mm 16 [5.3] 14.5 [7.0] 17 [6] 0.0042 17 [6.0]
LVEDD, mm 43 [8.3] 43 [9.5] 43 [8.25] 0.8285 43 [7.75]
LVESD, mm 30 [7.5] 29 [8.0] 30 [6.5] 0.2526 30 [6.25]
MAPSE, mm 9.0 [6.0] 10.5 [5.3] 8 [3.3] 0.0006 10 [5.75]
TAPSE, mm 14.0 [7.5] 17.0 [6.5] 14 [6] 0.1286 14 [7.0]
MASV, m/s 3 [3.125] 6.5 [3.5] 5.5 [2.25] 0.0496 6 [2.0]
E/A ratio 1.49 [1.43] 1.45 [0.66] 2.5 [2.5] 0.0982 1.67 [2.12]
E/e0 ratio 12.3 [9.2] 11.1 [5.0] 13.3 [9.2] 0.0497 12.5 [9.1]
LV hypertrophy index* 0.80 [0.32] 0.73 [0.34] 0.85 [0.32] 0.0061 0.79 [0.25]
LV ejection
fraction <40%
22 (31.4) 3 (8.0) 19 (56.0) <0.0001 22 (36.7)
Values are n (%) or median [interquartile range]. *LV hypertrophy index was calculated as the mean of the
septal and posterior wall divided by one-half of LV end-diastolic diameter (normal range 0.33 to 0.41) (27).
A ¼ late diastolic transmitral ﬂow velocity; ATTR ¼ transthyretin amyloidosis; E ¼ early diastolic trans-
mitral ﬂow velocity; e0 ¼ tissue Doppler–derived early diastolic peak velocity at lateral mitral annulus;
eGFR ¼ estimated glomerular ﬁltration rate according to the modiﬁcation of diet in renal disease study;
IVS ¼ interventricular septum; LV ¼ left ventricular; LVEDD ¼ left ventricular end-diastolic diameter;
LVESD ¼ left ventricular end-systolic diameter; MAPSE ¼ mitral annular plane systolic excursion; MASV ¼
mitral annular systolic velocity; MBMI ¼ modiﬁed body mass index (serum albumin  body mass index);
NA ¼ not applicable; NT-proBNP ¼ N-terminal pro–B-type natriuretic peptide; NYHA ¼ New York Heart
Association; PW ¼ posterior wall; SSA ¼ senile systemic amyloidosis; TAPSE ¼ tricuspid annular plane
systolic excursion; TTR-FAC ¼ transthyretin familial amyloid cardiomyopathy.
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5053¼ severe) in each of the 16 LV segments. Finally, the
sum of contrast-enhanced CMR intensity of all 16
segments was calculated to express global contrast-
enhancedCMRintensity (minimal¼ 0,maximal¼ 48).
Statistical analysis. Continuous data were expressed
as median (interquartile range). Categorical vari-
ables were expressed as absolute numbers (percent-
age). Data were compared between TTR-FAC and
SSA using the Mann-Whitney U or Fisher exact
test. Correlation analyses were performed using the
Spearman coefﬁcient. Cutoff values for all-cause
mortality and diagnosis of cardiac involvement by
scintigraphy were determined by receiver-operating
characteristic (ROC) analysis. Kaplan-Meier curves
plotted for cumulative all-cause mortality of patients
with cardiac amyloidosis (time between scintigraphy
and death) were analyzed using log-rank analysis
with right censoring. Using univariable and multi-
variable Cox regression models, the association of
parameters assessed by CMR, echocardiography,
electrocardiography, and laboratory analysis with all-
cause mortality were investigated. A stepwise for-
ward selection method was used for the entry and
retention of variables in the Cox proportional hazard
regression model, with all cause-mortality as a
dependent variable and univariate risk factors as
independent predictors (NT-proBNP, troponin T,
and LV hypertrophy index). A separate analysis was
performed in the subgroup of patients assessed by
CMR. A p value <0.05 was considered statistically
signiﬁcant. Statistical analyses were performed using
StatView version 5.0 (SAS Institute, Cary, North
Carolina).
RESULTS
Of 70 patients, 60 presented with cardiac involve-
ment. In 51 patients, cardiac involvement was
proved by endomyocardial biopsy; 1 of these pa-
tients with a positive endomyocardial biopsy spec-
imen did not meet noninvasive criteria of cardiac
involvement (septal thickness of 10 mm). This pa-
tient had an HR of 2.9% and no late gadolinium
enhancement by CMR. Some patients had clinical
evidence of further involvement of the gut (n ¼ 11),
peripheral nerves (n ¼ 20), lung (n ¼ 4), vitreous
body (n ¼ 3), and urinary bladder (n ¼ 2). Clinical,
electrocardiographic, and echocardiographic char-
acteristics of the study patients as well as the sub-
group of patients with cardiac involvement are
shown in detail in Table 1. Characteristics of the
subgroup of patients assessed by CMR (n ¼ 30) did
not differ from the whole patient cohort (data not
shown).Scintigraphic ﬁndings. The median WBR of
99mTc-DPD was 79.6% (20.8%), median HR was
6.4% (3.2%), and median ratio of heart-to-whole
body retention was 7.8% (3.9%). Comparison of
scintigraphic parameters in the subgroup with SSA
compared with TTR-FAC revealed no differences
regarding HR, WBR, and heart-to-whole body
ratio. WBR, HR, and heart-to-whole body ratio
correlated well with morphological parameters
(interventricular septum thickness, LV hypertrophy
index) as well as with plasma levels of cardiac
Table 2. Correlation of Scintigraphy and Clinical Parameters
Whole-Body
Retention
Heart
Retention
Heart-to-
Whole-Body
Retention
r p Value r p Value r p Value
IVS thickness 0.440 0.0002 0.533 <0.0001 0.405 0.0006
LV hypertrophy index* 0.425 0.0003 0.455 <0.0001 0.278 0.0206
Log troponin T 0.357 0.0032 0.549 <0.0001 0.447 0.0002
Log NT-proBNP 0.634 <0.0001 0.660 <0.0001 0.484 <0.0001
MASV 0.364 0.0021 0.526 <0.0001 0.442 0.0001
MAPSE 0.250 0.0379 0.470 <0.0001 0.413 0.0004
TAPSE 0.302 0.0125 0.326 0.0066 0.258 0.0333
eGFR 0.525 <0.0001 0.478 <0.0001 0.266 0.0263
*LV hypertrophy index was calculated as the mean of the septal and posterior wall divided
by one-half of LV end-diastolic diameter (27).
Abbreviations as in Table 1.
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correlation of WBR, HR, and heart-to-whole body
ratio was observed with functional parameters of
amyloid burden (mitral annular systolic velocity,
MAPSE, TAPSE) as well as renal function
(Table 2). No correlation was observed with age
and modiﬁed body mass index. The cutoff value of
HR for diagnosis of cardiac involvement with
highest sensitivity (80%) and speciﬁcity (90%) was
4.8% (area under the curve: 0.92  0.04; 95%
conﬁdence interval: 0.84 to 0.99; p < 0.0001). In
total, in 51 patients, HR above this cutoff was
observed.
Late gadolinium enhancement was observed in
28 of 30 patients (93.3%) assessed by CMR. A
signiﬁcant correlation between the extent of late
gadolinium enhancement by semiquantitative anal-
ysis with WBR (r ¼ 0.506, p ¼ 0.0071) as well as
HR (r ¼ 0.407, p ¼ 0.0350) was observed. Late
gadolinium enhancement correlated with troponin
T (r ¼ 0.613, p < 0.0001) and NT-proBNP
(r ¼ 0.620, p ¼ 0.0006).
Survival analysis. Survival analysis was performed in
the cohort of 60 patients with cardiac involvement.
In total, 25 of 60 patients died during a median
follow-up of 31.1 months (interquartile range: 31.3
months). Survival did not differ between patients
with SSA and TTR-FAC (p ¼ 0.213). All-cause
mortality was worse in patients with an HR and
heart-to-whole body ratio (but not WBR) above
the median compared with patients with HR
and heart-to-whole body ratio below the median
(Fig. 2). Univariate Cox regression revealed NT-
proBNP, troponin T, MAPSE, and LV hypertro-
phy index as predictors of outcome (Table 3). Based
on these results, NT-proBNP, troponin T, and LVhypertrophy index were included in the multivariate
Cox proportional hazards model with stepwise for-
ward regression. By multivariate analysis, troponin T
remained the only independent predictor of survival
(hazard ratio: 4.4, p < 0.05). There was no collin-
earity between troponin T and NT-proBNP. A
Kaplan-Meier curve for patients stratiﬁed by median
of troponin T is shown in Figure 3. By ROC analysis,
the troponin T cutoff value predicting all-cause
mortality with highest sensitivity (80%) and speci-
ﬁcity (68.7%) was 0.0375 mg/l (area under the curve:
0.746; 95% conﬁdence interval: 0.612 to 0.880; p ¼
0.002). Cox regression analysis of the subgroup of
patients assessed by CMR revealed troponin T as the
only predictor of survival (hazard ratio: 10.5; p <
0.05). When scintigraphy variables were included in
a multivariate model, none of them were indepen-
dent predictors of survival.
D I SCUSS ION
Cardiac involvement represents the major compli-
cation in both hereditary ATTR and SSA (2,9,11).
Noninvasive indicators of severity of ATTR and
predictors of survival are limited. The most
important ﬁnding of the present study is that
99mTc-DPD tracer retention correlates well with
established parameters indicating severity of cardiac
disease. For risk stratiﬁcation, troponin T emerged
as the only independent and powerful variable after
adjustment for NT-proBNP and LV hypertrophy
index.
Noninvasive diagnosis of cardiac ATTR. 99mTc-DPD
scintigraphy is a simple diagnostic tool that is well
established and widely available for skeletal imaging.
A decade ago, it was shown that this tool was
capable of identifying (cardiac) TTR amyloid
deposition by increased tracer retention (19).
In recent years, high sensitivity and speciﬁcity for
the detection of (cardiac) ATTR were demonstrated
by 99mTc-DPD scintigraphy (29). Finally, minor
tracer retention was reported in patients with light-
chain amyloidosis and advanced cardiac involve-
ment (30). Thus, it was concluded that absence of
cardiac tracer retention is almost pathognomonic for
light-chain amyloidosis, whereas the presence of
severe tracer retention is almost pathognomonic for
ATTR. Moreover, cardiac tracer retention can be an
incidental ﬁnding if skeletal imaging is performed in
older patients primarily to detect any skeletal
abnormality. The precise mechanism of bisphos-
phonate binding to amyloid remained unclear, but a
high calcium load in amyloid tissue was suggested to
be causative (31).
AB
C
Figure 2. Survival Analysis According to Scintigraphy Findings
Association of median of whole-body retention (WBR) (A), heart, sternum, and
thoracic spine tracer retention (HR) (B), and ratio of HR to WBR (HR:WBR) (C)
with survival.
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 7 , N O . 5 , 2 0 1 4 Kristen et al.
M A Y 2 0 1 4 : 5 0 2 – 1 0 Risk Stratiﬁcation in TTR Amyloidosis
507Although an age-dependent increase in tracer
retention may be suspected, no correlation of WBR
and HR with age was observed in this study. This
may be explained by the wide heterogeneity of
phenotypes in ATTR, with age at onset of amyloid
deposition ranging between 30 and 60 years and the
fact that almost one-half of the present patient
cohort consists of SSA patients with a mean age of
72.3 years.
Recently, in a smaller study consisting of 20 pa-
tients with 3 different variants of the TTR gene
(Glu89Gln, Phe64Leu, and Thr49Ala), it was de-
monstrated that detection of cardiac amyloid
deposition was more extensive and sensitive when
assessed by HR of 99mTc-DPD rather than by
late gadolinium enhancement (32). Even though
these variants were associated with polyneuropathy,
cardiomyopathy, and carpal tunnel ligament syn-
drome, HR was present in one-half of the patients.
According to these reports, this noninvasive tool
was increasingly used speciﬁcally as a surrogate for
cardiac amyloid load. However, detailed diagnostic
criteria for cardiac involvement have not been re-
ported previously.
In a previous study by Rapezzi et al. (30), com-
parison of mean values of 99mTc-DPD HR between
patients with TTR-related cardiac amyloidosis,
light-chain related cardiac amyloidosis, and con-
trols was performed. The same is true for the study
of Bokhari et al. (33) comparing mean heart-
to-contralateral ratio of technetium-99m pyro-
phosphate retention according to the subtypes of
amyloidosis, namely, light chain, mutant, as well as
wild-type ATTR. However, none of the studies
referred to a cutoff value of HR deﬁning cardiac
involvement. Thus, to the best of our knowledge,
this is the ﬁrst study reporting a ROC-derived
cutoff value for the deﬁnition of cardiac involve-
ment in ATTR. An HR of 4.8% indicated cardiac
involvement with an acceptable sensitivity (80%)
and speciﬁcity (90%).
Risk prediction of ATTR. Risk assessment in patients
with cardiac amyloidosis is crucial in clinical care.
Almost all strategies by electrocardiography and
echocardiography were derived in patients with
light-chain amyloidosis (15–18,34,35). Due to the
diversity of light-chain amyloidosis and ATTR, in-
dicators established in light-chain amyloidosis may
not apply to ATTR (12,36,37). Moreover, due to
the high speciﬁcity of 99mTc-DPD for cardiac
ATTR, this tool may have a potential impact on risk
assessment. At present, data on risk prediction by
echocardiography, cardiac biomarkers, CMR, and
99mTc-DPD scintigraphy in ATTR are limited.Although we were able to observe correlations of
different morphological and functional parameters
assessed by echocardiography and 99mTc-DPD
Table 3. Results of Univariate Cox Regression Analysis to Determine
Death in the Whole Patient Cohort
p Value Hazard Ratio 95% Conﬁdence Interval
Whole-body retention 0.8089 1.31 0.15–11.64
Heart retention 0.0702 15.31 0.80–293.61
Heart to whole body 0.0725 13.40 0.78–304.30
Sex 0.3361 0.62 0.23–1.65
MBMI 0.4487 1.00 1.00–1.00
Age 0.1687 1.03 0.99–1.07
Atrial ﬁbrillation 0.0836 2.06 0.91–4.68
QRS width 0.7471 1.01 0.99–1.01
IVS thickness 0.2225 1.06 0.97–1.17
LV hypertrophy index* 0.0235 6.12 1.28–29.32
E/e0 0.7868 0.99 0.95–1.04
E/A 0.7907 0.95 0.63–1.43
MAPSE 0.0167 0.85 0.74–0.97
TAPSE 0.1290 0.95 0.88–1.02
MASV 0.2322 0.85 0.66–1.11
eGFR 0.0927 0.99 0.97–1.00
Log NT-proBNP 0.0287 2.83 1.11–7.17
Log troponin T 0.0006 7.25 2.35–22.38
*LV hypertrophy index was calculated as the mean of the septal and posterior wall divided
by one-half of the LV end-diastolic diameter (27).
Abbreviations as in Table 1.
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508scintigraphy that were associated with the outcome
of ATTR, by multivariate analysis, troponin T
remained the only independent predictor of survival.
This appears to be in contrast to a recent report
from Rapezzi et al. (38) summarizing 63 ATTR
patients with a median follow-up of 14 months,Survival Analysis According to Troponin T
n of troponin T plasma level with survival stratiﬁed by the
alue.which demonstrated age and ﬁlling pattern as in-
dependent predictors of a combined endpoint of
death from cardiovascular causes (fatal arrhythmias
or severe worsening of heart failure), hospital stay
due to congestive heart failure, complete atrioven-
tricular block, atrial ﬁbrillation/ﬂutter, myocardial
infarction, or stroke. Information on predictors of
death in this study is lacking. There were only 2
deaths reported during follow-up. In a small cohort
of patients with wild-type ATTR, a decrease in
longitudinal myocardial function indicated by
MAPSE was predictive of survival (13). A previous
report on 34 patients (some with light-chain amy-
loidosis, some with ATTR) revealed LV fraction by
CMR and NT-proBNP as independent predictors
of survival (28), but subgroup analysis of light-chain
amyloidosis or ATTR was not performed.
In light-chain amyloidosis, increased levels of
troponin and NT-proBNP have been well estab-
lished as predictors of poor outcome (16,17).
Troponin T elevation has been shown to correlate
with a more aggressive disease and a shorter survival
(17,39), whereas NT-proBNP is helpful to assess
response to treatment (16). Both NT-proBNP and
troponins have been incorporated in a risk score
protocol widely used in clinical practice (40).
In a recent report on the use of cardiac bio-
markers (troponin T and I and B-type natriuretic
peptide) in late-onset Val30Met patients, neither
troponin T nor I was a surrogate for the presence of
cardiac amyloidosis as detected by echocardiography
(41). In these patients, abnormal values of B-type
natriuretic peptide were early indicators of heart
failure already present despite normal strain values
by echocardiography.
Study limitations. In the present study, a subgroup
of 30 patients was assessed by CMR. Although this
is a small patient cohort, it is by far a well-sized
number of patients with ATTR (28,42). Interest-
ingly, troponin T correlated well with the extent of
late gadolinium enhancement. Both troponin T and
late gadolinium enhancement are indicators of
myocardial damage, suggesting a potential impact of
late gadolinium enhancement on outcome; however,
this needs to be evaluated in a larger patient cohort.
As 99mTc scans impose an effective radiation dose of
approximately 3 mSv, its diagnostic use needs to be
compared with T1 mapping by CMR recently re-
ported as a noninvasive diagnostic tool for diagnosis
of cardiac amyloidosis (42).
In summary, 99mTc-DPD scintigraphy appears
to be a useful tool for noninvasive diagnosis of
ATTR (especially wild type) if cardiac biopsy is to
be avoided and if amyloid was established by
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509histology in any extracardiac organ. Nevertheless,
the prognostic value of 99mTc-DPD scintigraphy
appears to be limited.
CONCLUS IONS
In recent reports, it was demonstrated that
99mTc-DPD scintigraphy plays an important role
for the (differential) diagnosis of cardiac ATTR.
In the present report, it was demonstrated thatquantitative analysis of tracer retention relates to
cardiac involvement in ATTR; however, by multi-
variate analysis, troponin T remained the only in-
dependent predictor of all-cause mortality.
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